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Background and Objective: In multiple sclerosis (MS) patients, Double Inversion
Recovery (DIR) magnetic resonance imaging (MRI) can be used to detect cortical
lesions (CL). While the quantity and distribution of CLs seems to be associated with
patients’ disease course, literature lacks frequent assessments of CL volumes (CL-V)
in this context. We investigated the reliability of DIR for the longitudinal assessment
of CL-V development with frequent follow-up MRIs and examined the course of CL-V
progressions in relation to white-matter lesions (WML), contrast enhancing lesions (CEL)
and clinical parameters in patients with Relapsing-Remitting Multiple Sclerosis (RRMS).
Methods: In this post-hoc analysis, image- and clinical data of a subset of 24 subjects
that were part of a phase IIa clinical trial on the “Safety, Tolerability and Mechanisms of
Action ofBoswellicAcids in Multiple Sclerosis (SABA)” (ClinicalTrials.gov, NCT01450124)
were included. The study was divided in three phases (screening, treatment, study-end).
All patients received 12 MRI follow-up-examinations (including DIR) during a 16-months
period. CL-Vs were assessed for each patient on each follow-up MRI separately by two
experienced neuroradiologists. Results of neurological screening tests, as well as other
MRI parameters (WML number and volume and CELs) were included from the SABA
investigation data.
Results: Inter-rater agreement regarding CL-V assessment over time
was good-to-excellent (κ = 0.89). Mean intraobserver variability was 1.1%. In all
patients, a total number of 218 CLs was found. Total CL-Vs of all patients increased
during the 4 months of baseline screening followed by a continuous and significant
decrease from month 5 until study-end (p < 0.001, Kendall’W = 0.413). A positive
association between WML volumes and CL-Vs was observed during baseline screening.
Decreased CL-V were associated with lower EDSS and also with improvements of
SDMT- and SCRIPPS scores.
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Conclusion: DIR MRI seems to be a reliable tool for the frequent assessment of
CL-Vs. Overall CL-Vs decreased during the follow-up period and were associated with
improvements of cognitive and disability status scores. Our results suggest the presence
of short-term CL-V dynamics in RRMS patients and we presume that the laborious
evaluation of lesion volumes may be worthwhile for future investigations.
Clinical Trial Numbers: www.ClinicalTrials.gov, “The SABA trial”; number:
NCT01450124
Keywords: multiple sclerosis, cerebral cortex, inflammation, magnetic resonance imaging, cortical lesion volume,
double inversion recovery
INTRODUCTION
Recent clinical trials, neuropathological investigations and MRI
imaging studies have drawn growing attention to the relevance
of gray matter (GM) lesions and particularly cortical lesions
(CL) in Multiple Sclerosis (MS) patients (1–3). In contrast
to earlier assumptions (4, 5), recent studies reported that
neuroinflammation is present in CLs, suggesting that active
immune mechanisms and focal demyelination are present inside
the cortical layer (6–8). Histopathological reports revealed at
least a partial independence in the evolution of CLs and
white matter lesions (WML) (6, 9–11), suggesting different
underlying neuroimmunological pathomechanisms regarding
the development of both lesion-types. Moreover, CLs seem
to correlate more closely with the degree of disability than
the quantity of white matter lesions (WML) (2, 10, 12, 13).
However, a comprehensive and frequent in vivo assessment of
CLs is still challenging and little is known about structural
developments of CLs in MS patients. Therefore, advanced
imaging techniques, such as Double Inversion Recovery (DIR)
MRI have shown considerable benefits for the evaluation of
cortical lesion quantity and their distribution inside the cerebral
cortex. DIR imaging has been shown to increase the detection
rates of CLs inside the cerebral cortex and some comprehensive
longitudinal investigations reported significant correlations of
CL numbers (CL-N) with patients’ disability status (1, 14, 15).
While CL morphology remains unchanged over time (14),
this may not seem to apply for CL-V (1, 14–16). However,
current literature lacks longitudinal frequent assessments of
CL-V on DIR in this context. In this study, we had access
to a subset of longitudinal MRI data from the phase IIa
trial on the “Safety, Tolerability and Mechanisms of Action
of Boswellic Acids (BA) in Multiple Sclerosis (SABA)” (17).
This subset of RRMS patients underwent 12 MRI follow-up
examinations (including DIR sequences) within a 16-months
period enabling assessments of CLs at high sampling rates.
The aim of this post-hoc study was 2-fold: (1) to investigate
the reliability of DIR MRI for the assessment of CL-Vs and
Abbreviations: CEL, Contrast enhancing lesions; CL, Cortical lesions; CL-V,
Cortical lesion volume; DIR, Double Inversion Recovery; PASAT, Paced Auditory
Serial Addition Test; RRMS, Relapsing-remitting Multiple Sclerosis; SDMT,
Symbol Digit Modalities Test; WML, White matter lesion.
(2) to compare the course of CL-V progressions with those of
other MRI biomarkers and clinical screening parameters during
the follow-up period. We hypothesized that DIR MRI is a
reliable tool for longitudinal assessments of CL-Vs and that the
course of CL-V development is associated with clinical screening
parameters, but independent from that of WMLs and contrast
enhancing lesions (CEL), presumably due to their different
underlying pathomechanisms.
METHODS
Patients
This post-hoc study was approved by the local research Ethical
Committee Hamburg (Ethik-Komission der Ärztekammer
Hamburg) and the Federal Institute for Drugs and Medical
Devices (BfArM), following the guidelines of the Declaration of
Helsinki and written informed consent was given from every
participant. In total, 24 relapsing-remitting MS (RRMS) patients,
all diagnosed with definite MS based on the 2010 revised
McDonald criteria (18) were enrolled. The study cohort was a
subset of patients included in a phase IIa baseline-to-treatment
clinical trial on boswellic acids (SABA) (17) to treat active
RRMS (clinical trial number: NCT01450124). The inclusion
criteria for this subset of SABA patients were as follows: (1)
only patients with completed 16-month follow-up data were
included (i.e., all clinical and demographic data were completely
available and treatment maintained throughout the whole
follow-up period); (2) the MRI investigation was conducted at
the University Medical Center Hamburg-Eppendorf (data from
other centers were excluded); (3) all included patients completed
the full set of 12 DIR MRI. Baseline patients’ characteristics are
summarized in Table 1.
Background Information on the SABA
Study
SABA was designed as a multicenter baseline-to-treatment phase
IIa trial on patients with RRMS and Clinically Isolated Syndrome
(CIS) (17). The main study objective was to determine the safety
and tolerability of high dose BAs in MS patients to describe the
effect on disease activity. The trial was divided into 3 phases:
Months 1–4 were considered as “screening phase” (SP), which
delivered baseline disease activities without immunotherapy.
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TABLE 1 | Patients’ baseline characteristics.
Demographic data n = 24
Age (years)-mean (SD) 38 (11)
Sex–female/male 20/4
EDSS (0–10 points)-median (IQR) 2.0 (1.5, 2.5)
Disease duration (years)-median (IQR) 7.4 (2.6, 11.5)
EDSS, Expanded Disability Status Scale; Data are presented as mean or median values
or absolute numbers as indicated.
Treatment with BAs was initiated at the beginning of month 5
and was maintained as long as the subject tolerated the drug.
During months 5–7, patients were assessed for the tolerability
and safety of the drug. The 4-months interval between 9 and 12
were regarded as “treatment phase” (TP), since noticeable therapy
effects, i.e., visible on MRI images, were expected in that period.
The end of the study was at month 16 and hence was declared as
“study-end” (SE). Based on the SABA study regulations (17), MRI
scans were conducted monthly, together with clinical screening
tests, except for months 8 and 13–15. All patients were treated
with BA doses up to 1,500 mg/3 times a day and received no
corticosteroids or other immunomodulating substances for at
least 3 months before entering the study.
Clinical Scores
Results from patients’ clinical neurological screening tests were
taken from the main study data of SABA. Neurological screening
included the Expanded-Disability-Status-Scale (EDSS) (19), the
Paced Auditory Serial Addition Test (PASAT) (20) and the
“Symbol Digit Modalities Test” (SDMT) (21). SDMT values
are presented in relation to normative data from an age-
matched and education-adapted normal population. Negative
values represent a standard deviation below the age-matched and
education-adapted normal population, indicating inferior test
results of the patient and vice versa. Furthermore, the SCRIPPs
neurological rating scale (22), as an additional disability measure,
was acquired.
MRI Image Acquisition
MRI examinations were conducted on a 3T MR scanner (Skyra,
SiemensMedical Systems, Erlangen, Germany) with a 32-channel
head coil. The MR protocol consisted of axial 2D T2w turbo spin
echo (TSE) images acquired with TR = 2800ms, TE = 90ms, 43
slices, Matrix: 192 × 256, slice thickness = 3mm and in plane
resolution= 0.5× 0.5mm2, turbo factor= 5; 3D-FLAIR images
with TR = 4700ms, TI = 1800ms, TE = 390ms, 192 slices,
slice thickness = 1mm, matrix = 256 × 256; 3D DIR sequences
were acquired with TR= 7500ms, TE= 321ms, TI1= 3000ms,
TI2= 450ms, 192 slices, slice thickness= 1.4mm, matrix= 256
× 256, in plane resolution = 1.4 × 1.4mm2; T1-MPRAGE pre
and 5min post Gadolinium with TR = 1900ms, TE = 2.43ms,
TI= 900ms, slice thickness= 1mm, matrix= 256× 256× 192,
voxel size = 1 × 1 × 1mm and Gadolinium-dose of 0.2ml per
kilogram of body weight.
Image Analysis
Image data were processed using the software package FSL 5.0
(Analysis Group, FMRIB, Oxford, UK). Lesion segmentation
was performed with the software package Analyze 11.0 (Analyze
Direct, Overland Park, KS, USA). All MRI examinations were
assessed by two experienced neuroradiologists (T.F. and G.B.).
CL identification was performed using a similar lesion scoring
approach as described in (14). In brief: In a first reading step,
CL-N and CL-V were assessed by each reader separately on
correspondent DIR scans of each patient in random order.
Hereafter, intraobserver and inter-rater reliability was computed.
Intraobserver reproducibility was tested as described in (1).
One observer (T.F.) evaluated all DIR scans of 24MS patients
3×. The intraobserver variability was calculated by using the
coefficient of variation, defined as the standard deviation (SD)
of a random variable divided by its mean value (1). Secondly,
consensus reading was performed and both readers judged on
unclear or disputatious CLs together. Thirdly, each CL was
numbered and traced throughout the follow-up of a patient by
using a side-by-side comparison. Hereby, identified CLs were
tracked as the same lesions in all follow-up MRI and new
CLs were clearly identifiable as such during the time-course.
CLs were manually selected and CL-Vs were delineated using
a semi-automatic threshold-based region growing segmentation
approach. Threshold-based lesion volumetry on DIR has
successfully been utilized in related imaging studies (1, 14,
15). CL scoring was performed applying the “MAGNIMS
consensus recommendations for MS cortical lesion scoring”
(23). Consequently, two subtypes of CLs were differentiated,
namely pure intracortical lesions and mixed gray/white matter
lesions (consisting of leukocortical/juxtacortical lesions). For
longitudinal CL-V analysis, both subtypes were considered, as
proposed in the MAGNIMS consensus recommendations (24)
and mean CL-V/follow-up visit (in mm3) for each patient
was acquired. The number and volume (mm3) of WMLs and
new WML/follow-up, the number of CELs, as well as new
CEL/follow-up were taken from the SABA study data of each
patient and included in our analysis.
Statistical Analysis
Results were presented as mean (standard deviation, SD), median
(25th percentile and 75th percentile) for continuous variables,
depending on the distribution or frequencies with percentages
for categorical variables. The change of CL-V and CL-N over
a 16-month period were explored by using Friedman test and
the effect size of Kendall’W was reported. A linear mixed
model (LMM) was employed to describe the trend of CL-
V over time and to assess the influence of MRI and clinical
parameters. Hence, CL-V was set as dependent variable of the
model with the time point of assessment in months as fixed
factor. We explored the association of age, sex, and duration of
disease, which was not significant. WML number and volume,
CEL number, and the neurological screening parameters EDSS,
SDMT, PASAT, and SCRIPPs were set as covariates of the model.
A random intercept for the patient ID was included in the
model to account for cluster correlation in the data. A first-
order autoregressive structure with heterogeneous variances was
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assumed for the covariance structure. Interobserver reliability
was assessed computing Cohen’s κ. All statistical analyses were
performed using SPSS software (IBM Corp. Released 2016. IBM
SPSS Statistics for Windows, Version 24.0. Armonk, NY: IBM
Corp.) and all graphics were created with Stata (Version 15SE;
Stata Corp. 2017, College Station, TX). The significance level was
considered as p-value ≤ 0.05 (two-sided).
RESULTS
Reliability of Cortical Lesion Volume
Assessment
Overall mean inter-rater agreement regarding CL-V assessment
in all follow-up examination was good-to-excellent (κ = 0.89).
Mean intraobserver variability was 1.1%.
Cortical Lesion Volume Development
Figure 1 displays examples of CL-V progressions and Figure 2
displays the development of median CL-V over time (by
month), together with the corresponding 25th percentile and
75th percentile. Median CL-Vs increased during 4 months of
baseline SP and then continuously and significantly decreased
frommonth 5 until SE (p< 0.001, Kendall’W= 0.413). Summary
measures (Supplementary Table 1) for median CL-Vs in all
patients in the respective study phases were as follows: A median
CL-V of 134.8 mm3 (7.3–1490) was detected during baseline
SP. During TP, the median CL-V decreased to 91.7 mm3 (3.7–
1239.6). At SE, a median CL-V of 65.1 mm3 (0–995.7) was
measured. LMM analysis was performed to evaluate associations
of the course of CL-V development and other MRI biomarkers.
During baseline SP, a significant relationship between CL-V and
WML volume (p = 0.03) and EDSS (p = 0.04) was detected
(not displayed). To further explore the factors associated with
a decrease of CL-V after baseline SP, LMM analysis between
months 5 to 16 was performed (Table 2). In this period, lower
CL-Vs were associated with lower EDSS scores (p = 0.05) and
higher SDMT (p = 0.048) and SCRIPPs scores (p = 0.006).
No significant association was found between CL-V and WML
number (p= 0.526) or volume (p= 0.881) or CELs (p= 0.287).
Cortical Lesion Quantification
A total number of 218 CLs were found by consensus. At baseline
scan, at least one CL was found in 23/24 patients. One hundred
and Sixty one CLs (∼ 74%) were considered as mixed gray/white
matter lesions (leukocortical lesions/juxtacortical lesions),
whereas 57 CLs (∼26%) were regarded as pure intracortical
lesions. We detected a significant increase of total CL-Ns (p
< 0.001, Kendall’W = 0.748), but fewer new CLs/follow-up
emerged (p < 0.001, Kendall’W = 0.227) during the 16-months
observation period (Figure 3). Supplementary Table 1 displays
summary measures of (new) CLs in the related study-phases.
Contrast Enhancing Lesions
In accordance with findings of the SABA study, a reduction of
CELs during the observation period was detected (Figure 3).
There was a statistically significant decrease of CEL numbers (p
FIGURE 1 | Examples of cortical lesion volume changes during follow-up. This
figure displays cortical lesion volume (CL-V) changes of several lesions followed
over the time course in different MS patients. Distinct volume reduction of a CL
in the frontal cortex (A) marked with a white arrow at month 2 of screening
phase (SP, left side) and month 3 of treatment phase (TP, right side). Rather
marginal, but still notable CL-V reductions found in the cortices of patients in
(B) (1st month of SP left and 2nd month of TP right) and (C) (2nd month of SP
left and SE right). White arrow in (D) (4th month of SP left and 1st month of TP
right) points at a cortical lesion with a measurable volume decrease. Dotted
white arrow is indicating a CL with no measurable volume change.
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FIGURE 2 | Cortical lesion volume progression during follow-up. This figure
displays the progression of the cortical lesion volume (CL-V) during the time
course. From month 1–5, CL-V is fluctuating with a tendency to an increase of
volume. From month 5 onwards, a continuous decrease of CL-V was
detected. n = 24. The circles represent the median values with the
corresponding 25th percentile and 75th percentile.
TABLE 2 | Cortical lesion volume progression in relationship with MRI and clinical
parameters.
Factors Unstandardized
coefficient
95% CI of
unstandardized
coefficient
p-value
Intercept −268.91 −514.63 to −23.20 0.032*
Time (months) −7.39 −10.46 to −4.32 0.002*
SCRIPPs −3.29 −5.59 to −0.99 0.006*
PASAT 0.57 −0.35 to 1.49 0.211
SDMT −6.38 −16.38 to −3.62 0.048*
EDSS 12.64 0.02 to 25.30 0.050*
WML volume −0.0001 −0.004 to 0.004 0.881
Number of
WML
−0.507 −2.09 to 1.07 0.526
Number of
CEL
1.89 −1.65 to 5.43 0.287
This table displays the results of the general linear model regarding the progression of
Cortical Lesion Volume (CL-V) from month 5 (treatment onset) to month 16 (study end).
Since months 1–4 showed no significant trend in CL-V dynamics, this period was not
included in this analysis. The dependent variable in this model was CL-V. WML, white
matter lesion; CEL, contrast enhancing lesions; EDSS, Expanded Status Disability Scale;
SDMT, Normative Symbol Digit Modalities Test; PASAT, Paced Auditory Serial Addition
Test (out of 60 possible answers); SCRIPPs, score of disability measurement; significant
values (p ≦ 0.05) are marked by an asterisk.
< 0.001, Kendall’W= 0.180) and new CEL/follow-up (p< 0.001,
Kendall’W= 0.154) during follow-up (Figure 3).
T2w White Matter Lesion Numbers and
Volumes
Summary median WML values are displayed in
Supplementary Table 1. During the 16-months observation
period, the total number of WML lesions (p < 0.001,
Kendall’W = 0.832) and new WML/follow-up (p = 0.008,
Kendall’W = 0.097) increased significantly. Figure 3 depicts the
course of median WML per follow-up month.
DISCUSSION
CL-V development has been assumed to be independent
from WML evolution, but seems to be associated with the
progression of patients’ disability status and clinical course (10,
14, 25). Therefore, standardized assessments of CL-Vs may be
worthwhile and of potential to be used to optimize patient
care in clinical routine. Advanced MRI techniques, such as
DIR, may not only reveal the quantity of CLs located in the
cerebral cortex, but may also be suitable for CL-V assessment
(26). However, longitudinal, high sampling rate evaluations of
CL-V development on DIR are scarce and literature yet lacks
a comprehensive investigation with patients incorporated in
a standardized imaging and treatment protocol. In this post-
hoc analysis, we aimed to frequently assess the development
of CL-Vs in a subset of RRMS patients from the SABA
trial (17). We observed small, but notable short-term CL-V
dynamics in all included patients. Overall CL-Vs did not change
significantly during the 4 months of SP, while a decrease of CL-
V was evident during follow-up. Intrarater variability regarding
CL-V assessment on DIR was comparably small (1.1%) and
overall inter-observer agreement on DIR images was good-to-
excellent. We conclude that DIR MRI is a reliable tool for CL-
V assessments and presume that the evaluation of CL-Vs may
hold promising potentials for comprehensive future clinical-
radiological investigations in MS patients.
CLs in general and, with restrictions, CL-Vs have been
evaluated in some recent longitudinal DIR MRI studies
incorporatingMS patients. However, most of these investigations
conducted only very few follow-up timepoints, restricting their
ability to determine the reliability of DIR for the assessment
of CL-V (1, 14, 15). However, unanimously, many recent
studies reported of de-novo formations of CLs even within short
time intervals, which seem to be correlated with the patients’
individual disability status 13, 14, 10, 27, 16]. In contrast, only
very few comparable imaging studies exist, which analyzed
inter-rater reliabilities or intraobserver variances regarding the
detection rates of CLs (and CL-Vs) (1, 14, 15). However, the
intraobserver variance and inter-rater reliability detected in our
investigation was slightly better compared to the referred studies.
One explanation may be that the overall average CL-Vs detected
in our cohort were larger compared to the related studies.
This presumption is supported by other imaging studies, which
reported that lesions with greater lesion volumes (on DIR and
other MRI sequences) may be detected more reliably by the
investigators (14, 16, 27). Our results suggest that DIR MRI is a
reliable tool for the frequent assessment of CL-Vs in MS patients.
Comparable longitudinal studies reported of discordant
associations of CL-Vs with clinical parameters. A 3-year
longitudinal study by Calabrese et al. (1) including 76 RRMS
patients reported of a significant increase of CL-V especially
in RRMS patients with a clinical worsening reflected by
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FIGURE 3 | Development of the course of cortical-, white-matter- and contrast enhancing lesions. Boxplots in this figure display the development of lesion numbers
and the number of new lesions during the 16-month observation period (n = 24). CL, cortical lesion; WML, white matter lesion; CEL, contrast enhancing lesion.
EDSS changes. Moreover, CL-V at baseline scans correlated
significantly withWML-volume, disease duration and EDSS. The
authors stated that CL-V predicted disability accumulation over
the study period. Another study by Calabrese et al. (14) also
assessed CL-V changes in a cohort of RRMS and SPMS patients
during a time space of 1-year. The authors did not find any
significant changes in CL-V after 1-year compared to baseline
measures, while CL-N increased during follow-up. A study by
Mike et al. (27), though not longitudinal in nature, reported of
correlations of CL-V with WML volume and CL-N, but also with
SDMT and EDSS measures. Furthermore, the authors found a
trend toward higher CL-V with disease duration and progression
when comparing early RRMS vs. late RRMS patients. These
results are in accordance with our findings, since we also detected
an association between CL-Vs and EDSS, SDMT and SCRIPPs
scores during follow-up. CL-V showed a relationship with WML
volume during SP, but was not associated with either the course
of WML number or volume, or parameters of disease activity
(CEL) after treatment initiation. This finding supports the claim
of an at least partial independence of CL-V development from
parameters of WM inflammation, which was raised in previous
reports (1, 6, 8, 15). However, all these findings support the
assumption that (the magnitude of) CL-V indeedmay be another
useful biomarker related with patients’ disability status and
clinical course, justifying the laborious evaluation of these lesions.
Nevertheless, although the assessability of CLs has clearly been
improved by advanced imaging techniques such as DIR or Phase-
Sensitive Inversion Recovery (26, 28), lesion identification is still
challenging (10, 16, 23) and time-consuming and therefore may
not be easily utilized outside of a research environment. For the
future, automated lesion identification tools or machine learning
algorithms under supervision of an experienced neuroradiologist
may enable fast and reliable CL-N and CL-V quantifications,
which may pave the way for the evolution of CL dynamics
in the clinical routine. Notably, promising results in this field
have just recently been reported for automated WML detection
approaches (29).
While many investigations focused on microstructural and
cellular composition of CLs (5, 6, 8, 10, 13, 30, 31), little
is known about the underlying pathophysiology of CL-V
changes. In contrast to the assumption that specific widespread
histo- and immuno-pathological patterns of focal inflammation,
which are evident in WMLs, are missing in case of cortical
demyelination (4, 5, 8), current data suggest that CLs indeed
hold extensive amounts of inflammatory components (6–
8). Histopathologically, the majority of CLs contain T-cell
infiltrates, B-cell follicle-like-structures, as well as conglomerates
of microglia, lymphocytes and macrophages, suggesting a direct
role of these inflammatory cells in cortical inflammation (6).
Interestingly, mixed gray/white matter lesions (which represent
most CLs detected in our study) seem to be more inflammatory
than subpial or pure intracortical lesions (6). It may be
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conceivable, albeit speculative, that CL-V sizes are connected
to the magnitude of cortical inflammation and thus may be
targeted by anti-inflammatory treatments. Whether a decline of
CL-V may appear due to a reduction of cellular inflammatory
components or due to an anti-oedematous effect needs to
be objective of further investigations including a control
group. As for now, it is unclear if our findings display the
natural history of the disease (with improvement or resolution
of acute flare) or any kind of treatment response. Future
longitudinal investigations including greater amounts of subjects,
histopathological specimens and different treatment regimens
may reveal the implications of CL-V progressions for patients’
individual disease course, degree of cortical inflammation and
relapse status.
Our study holds some limitations: Due to the high
frequency of almost monthly follow-ups, a “learning-effect”
to the clinical screening tests, especially for the evaluation of
neurocognitive functioning is evident. Therefore, no valid claims
regarding associations between neurocognitivemeasures andCL-
V evolution can be made. Our study model intrinsically does not
hold a control group. Any claims about treatment effects of BAs
are not scope of the manuscript. The follow-up period of this
study is relatively short. Long-term alterations of CL-Vs need
to be investigated in more extended longitudinal studies. DIR
sequences are prone to artifacts and suffer from a comparably low
signal-to-noise ratio. It has been reported, that only a minority of
CLs are actually visible on DIR scans and that the classification of
distinct CL types can be challenging (10, 16). Therefore, we used
a two-reader consensus approach tominimize misinterpretations
of CL-N and CL-V accordingly. However, we cannot exclude that
in some cases, due to the technical limitation of the sequence,
CL-Vs may be slightly over- or under-estimated.
CONCLUSION
DIR MRI seems to be a reliable tool for the assessment of
CL-V development over time. CL-V decreased evidently
during follow-up, indicating short-term structural and
quantitative lesion dynamics in RRMS. CL-V was not associated
with the course of WML number and volume or CELs,
supporting the assumption of different pathophysiological
(inflammatory) mechanisms affecting the emergence and
the progression of these biomarkers. We conclude that the
laborious evaluation of CL-Vs may be worthwhile and should be
further investigated in future clinical studies including healthy
control groups.
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